Japan Approves Alpha DaRT for Head and Neck Cancer
Alpha Tau Medical has received marketing approval in Japan for its Alpha DaRT® radiation therapy. The treatment is authorized for patients with unresectable locally advanced or locally recurrent head and neck cancer. This marks the first clinical authorization for the therapy outside of Israel and will initiate a post-market surveillance program to gather further data.
- The therapy, called Diffusing Alpha-emitters Radiation Therapy (DaRT), works by inserting seeds coated with Radium-224 directly into the tumor. As the radium decays, it releases alpha-emitting atoms that diffuse a few millimeters, delivering high-energy alpha particles that cause irreparable double-strand breaks in cancer cell DNA. - This diffusion mechanism was designed to overcome a major limitation of alpha particles: their extremely short travel distance in tissue (typically less than 100 micrometers), allowing the treatment to destroy a larger tumor volume while sparing surrounding healthy tissue. - The core technology was invented at Tel Aviv University by a physicist, Professor Itzhak Kelson, and a professor of human microbiology, Yona Keisari, showcasing a career path that blends physics and biology to create new medical devices. - In clinical trials involving 81 head and neck or skin cancer tumors, Alpha DaRT demonstrated an 89% complete response rate, meaning the tumor was completely eliminated. The two-year local recurrence-free survival rate was 77%. - Bringing a therapy like this from an idea to patient use involves a wide range of life science careers. Tech-focused roles like biomedical engineering and bioinformatics are needed to develop the device, while patient-facing roles like radiation oncology and clinical research management are required to test it and administer it safely to patients. - The approval in Japan, the world's third-largest healthcare market, is a significant commercial milestone. A Japanese partner, HekaBio K.K., led the local approval process, a 7-year effort described as an "extremely rare event" for a foreign-developed medical device to be approved in Japan before the U.S. or Europe. - Beyond just killing cancer cells, preclinical and emerging clinical evidence suggests the treatment may act like an "in-situ vaccine" by stimulating an anti-tumor immune response that could help the body fight metastases.
